Related Experiment Videos
Penicillin-resistant pneumococcal meningitis in Israel
T Steinberg1, A Rachmel, Z Samra
1Department of Pediatrics, Schneider Children's Medical Center of Israel, Petah Tiqva, Israel.
Israel Journal of Medical Sciences
|January 22, 1998
Summary
Penicillin-resistant Streptococcus pneumoniae (PRP) meningitis is a global health threat. A case in Israel highlights treatment challenges and suggests vancomycin as a viable therapeutic option.
Area of Science:
- Infectious Diseases
- Microbiology
- Pediatrics
Background:
- Penicillin-resistant Streptococcus pneumoniae (PRP) poses a significant global health challenge.
- Meningitis caused by PRP has led to treatment failures and fatalities worldwide.
- No previous cases of PRP meningitis had been reported in Israel.
Observation:
- An 11-month-old infant in Israel presented with meningitis.
- The infant's condition did not improve with initial cefotaxime treatment.
- The causative agent was identified as penicillin-resistant Streptococcus pneumoniae.
Findings:
- The infant's PRP isolate exhibited minimal inhibitory concentrations (MICs) of 1.0 µg/ml for penicillin and cefotaxime, and 4.0 µg/ml for cefuroxime.
- Subsequent treatment with vancomycin resulted in a prompt clinical cure.
- This case represents the first reported instance of PRP meningitis in Israel.
Implications:
- Vancomycin is an effective treatment option for penicillin-resistant Streptococcus pneumoniae meningitis.
- The findings necessitate a review and potential update of meningitis treatment guidelines in Israel.
- Increased vigilance and awareness regarding PRP meningitis are crucial for healthcare providers in Israel.